How to manage thyroid eye disease: recent advances - a narrative review. (PubMed, Drugs Context) - Sep 16, 2026 - "The advent of targeted biologic therapies, particularly teprotumumab, as well as rituximab and tocilizumab, has significantly expanded therapeutic options and enabled a more personalized, phenotype-driven approach. Despite these advances, challenges related to accessibility, cost, long-term safety and optimal patient selection persist. Ongoing research and international collaboration are expected to refine management strategies and enhance the quality of life of patients with TED."
Journal • Review • Endocrine Disorders • Grave's Disease • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease
|
|
Georgios K Markantes; Grigoris Effraimidis; Katerina Saltiki; Marina Michalaki; Olga Karapanou
|